Clinical Trial Update: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination [Phase 3]

View source ↗

Summary

Phase 3 trial update reports antibody persistence at ages 3.5 and 4.5 years after primary and booster vaccination with DTaP-IPV-HepB-PRP~T or Infanrix Hexa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DTaP-IPV-HepB-PRP-T
• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED